Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: Evidence from POWER

Medicine & Life Sciences

• Darunavir 90%
• Highly Active Antiretroviral Therapy 67%
• CD4 Lymphocyte Count 61%
• Ritonavir 55%
• HIV 41%
• Protease Inhibitors 39%
• Costs and Cost Analysis 37%
• Therapeutics 9%
• HIV Protease Inhibitors 7%
• Anti-Retroviral Agents 7%
• Cost Control 6%
• Budgets 6%
• Health Care Costs 4%
• Delivery of Health Care 3%
• Morbidity 3%
• Mortality 2%
• Population 2%

Social Sciences

• active therapy 100%
• costs 33%
• evidence 25%
• cost of acquisitions 10%
• Healthcare 8%
• Belgian 6%
• social stratum 5%
• morbidity 5%
• mortality 4%
• budget 4%